Byetta is one among the many newer drugs which treat Type 2 diabetes, in a class known as incretin mimetics. Approved by the FDA in 2005, over thirty reports came into the FDA regarding adverse health events within the next two years. Those thirty people developed pancreatitis after taking Byetta; twenty-two of those had symptoms severe enough to result in hospitalization. Over half of these people saw their symptoms alleviated once Byetta was discontinued. Since that time there have been at least two deaths attributed to Byetta, and more reports sent to the FDA. Research has pointed to a link between Byetta and thyroid cancer, pancreatic cancer and pancreatitis, and while the drug has not been recalled, the number of lawsuits against the manufacturer of Byetta has been steadily increasing.